September 2024: European Academy of Dermatology and Venerology
ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes
September 2024: Bradykinin Symposium
Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
September 2024: Bradykinin Symposium
Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)
June 2024: Eastern Allergy Conference
Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
June 2024: European Academy of Allergy and Clinical Immunology
Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)
June 2024: European Academy of Allergy and Clinical Immunology
Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody
May 2024: Society for Investigative Dermatology Annual Meeting
Preclinical Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody
February 2024: American Academy of Allergy, Asthma, and Immunology
Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
December 2023: World Allergy Congress
Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results
November 2023: American College of Allergy, Asthma, and Immunology
Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results
